<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03441555</url>
  </required_header>
  <id_info>
    <org_study_id>M16-186</org_study_id>
    <secondary_id>2017-002531-42</secondary_id>
    <nct_id>NCT03441555</nct_id>
  </id_info>
  <brief_title>A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>Phase 1b Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sumitomo Dainippon Pharma Oncology, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, dose-escalation study to assess the safety and pharmacokinetics (PK), to
      determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to
      assess the preliminary efficacy of alvocidib with venetoclax when co-administered in
      participants with relapsed or refractory (R/R) acute myeloid leukemia (AML).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 30, 2018</start_date>
  <completion_date type="Anticipated">July 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 21, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tmax of venetoclax</measure>
    <time_frame>Approximately 32 days after first dose of study drug</time_frame>
    <description>Time to maximum plasma concentration (Tmax) of venetoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance of Alvocidib</measure>
    <time_frame>Approximately 32 days after first dose of study drug</time_frame>
    <description>Clearance (CL) of alvocidib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ of Alvocidib</measure>
    <time_frame>Approximately 32 days after first dose of study drug</time_frame>
    <description>Area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) post-dose of alvocidib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Venetoclax</measure>
    <time_frame>Approximately 32 days after first dose of study drug</time_frame>
    <description>Maximum plasma concentration (Cmax) of venetoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (t1/2) of Alvocidib</measure>
    <time_frame>Approximately 32 days after first dose of study drug</time_frame>
    <description>Half-life (t1/2) of alvocidib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24 Post-dose of Venetoclax</measure>
    <time_frame>Approximately 32 days after first dose of study drug</time_frame>
    <description>Area under the plasma concentration-time curve from 0 to 24 hours (AUC24) post-dose of venetoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Alvocidib</measure>
    <time_frame>Approximately 32 days after first dose of study drug</time_frame>
    <description>Maximum plasma concentration (Cmax) of alvocidib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt Post-dose of Alvocidib</measure>
    <time_frame>Approximately 32 days after first dose of study drug</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to time t (AUCt) post-dose alvocidib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Escalation Phase: Recommended Phase 2 dose (RPTD) for Venetoclax and Alvocidib</measure>
    <time_frame>Minimum first cycle of dosing (up to 28 days)</time_frame>
    <description>RPTD will be determined using available safety and pharmacokinetics data upon completion of the dose escalation phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) Rate</measure>
    <time_frame>Up to approximately 8 months</time_frame>
    <description>CR is defined as the proportion of participants with documented complete response (CR) based on International Working Group (IWG) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined CR Rate</measure>
    <time_frame>Up to approximately 8 months</time_frame>
    <description>Combined CR rate is defined as CR + CRi (CR with incomplete blood count recovery) based on IWG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 18 months</time_frame>
    <description>ORR is defined as the proportion of participants with documented partial response (PR) or better based on IWG criteria.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>Venetoclax + Alvocidib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax administered orally once daily (QD) and Alvocidib administered as an intravenous infusion on Days 1, 2, and 3 for all 28-day treatment cycles. Different combinations of dose levels for venetoclax and alvocidib may be explored.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>tablet, oral</description>
    <arm_group_label>Venetoclax + Alvocidib</arm_group_label>
    <other_name>ABT-199</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alvocidib</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Venetoclax + Alvocidib</arm_group_label>
    <other_name>Flavopiridol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have adequate coagulation, hematology, kidney, and liver function, per protocol.

          -  Diagnosis of relapsed or refractory (R/R) acute myeloid leukemia (AML)

          -  Meet the following disease activity criteria:

          -  an established, confirmed diagnosis of AML by World Health Organization criteria
             excluding acute promyelocytic leukemia (APL)-M3; and

          -  an Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
             2.

          -  If male participant is sexually active, he must agree from day 1 through 6 months
             after the last dose of alvocidib or 90 days after the last dose of venetoclax,
             whichever is longer, to practice the protocol-specified protection.

        Exclusion Criteria:

          -  History of any malignancy within the last 6 months except for those specified in this
             protocol and low-grade malignancies not requiring active treatment such as
             non-melanoma skin cancer, cervical intraepithelial neoplasia, or prostate cancer in
             situ.

          -  Prior allogeneic stem cell transplant within 6 months of study drug administration and
             no requirement for graft versus host therapy.

          -  History of previous enrollment in Studies NCT02993523 or NCT03069352.

          -  History of exposure to alvocidib or any other cyclin-dependent kinase 9 (CDK9)
             inhibitor.

          -  History of Tumor Lysis Syndrome (TLS) due to previous exposure to venetoclax.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC Norris Cancer Center /ID# 170844</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Irvine /ID# 201093</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center - Main /ID# 170799</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer /ID# 170761</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136-1002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Blood &amp; Marrow Transpl /ID# 170793</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center /ID# 201559</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016-6402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College /ID# 170800</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center /ID# 170842</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medic /ID# 170790</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Dresden /ID# 168636</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Klinik Eppendorf Hamburg /ID# 168633</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales /ID# 202302</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4EN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital /ID# 202304</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James University Hospital /ID# 202303</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 16, 2018</study_first_submitted>
  <study_first_submitted_qc>February 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2018</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Acute Myeloid Leukemia (AML)</keyword>
  <keyword>relapsed Acute Myeloid Leukemia</keyword>
  <keyword>refractory Acute Myeloid Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Alvocidib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

